Expressions and clinical significances of microRNA-126 and microRNA-7 in esophageal squamous cell carcinoma

doi:10.3760/cma.j.issn.1673-422X.2013.12.018

Abstract

Abstract: ObjectiveTo detect the expressions of microRNA126 (miR126) and microRNA7 (miR7) in esophageal squamous cell carcinoma (ESCC) and to analyze their correlations with clinicopathologic features and prognosis of ESCC. MethodsThe expressions of miR126 and miR7 in 116 ESCC samples and matched normal tissue samples were detected by realtime PCR. Statistical analysis was used to find the relationships among the expressions of miR126 and miR7, pathological characteristics and prognosis. ResultsLow expression, normal expression and high expression of miR126 were found in 73 (62.9%), 35 (30.2%) and 8 (6.9%) carcinoma samples respectively. Low expression, normal expression and high expression of miR7 were found in 52 (44.8%), 35 (30.2%) and 29 (25.0%) carcinoma samples respectively. The diseasefree survival in patients with low expression of miR126 and miR7 was shorter than that in patients with nonlow expression (χ2=4.268, P＜0.05; χ2=4.993, P＜0.05). The low expression of miR126 was correlated with tumor location, family history and drinking (χ2=14.564, P＜0.05; χ2=5.691, P＜0.05; χ2=4.971, P＜0.05), but was uncorrelated with gender, age, differentiation, infiltration, lymphatic metastasis and smoking (all P＞0.05). The low expression of miR7 was uncorrelated with pathological characteristics of ESCC (all P＞0.05). Conclusion The low expressions of miR126 and miR7 may be related to the prognosis of patients with ESCC, and have a certain clinical detection significance.

Key words: Esophageal neoplasms, Prognosis, MicroRNA-126, MicroRNA-7

WANG Jiang-Feng, LING Zhi-Qiang, MAO Wei-Min. Expressions and clinical significances of microRNA-126 and microRNA-7 in esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2013, 40(12): 936-940.

References

［1］ GriffithsJones S. The microRNA registry. Nucleic Acids Res, 2004, 32(Database issue): D109111. ［2］ Lewis BP, Burge CB, Bartel DP, et al. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 2005, 120(1): 1520. ［3］ Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2): 6990. ［4］ Meister J, Schmidt MH. miR126 and miR126*: new players in cancer. ScientificWorldJournal, 2010, 10: 20902100. ［5］ Tavazoie SF, Alarcón C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 2008, 415(7175): 147152. ［6］ Li XM, Wang AM, Zhang J, et al. Downregulation of miR126 expression in colorectal cancer and its clinical significance. Med Oncol, 2011, 28(4): 10541057. ［7］ Feng R, Chen X, Yu Y, et al. miR126 functions as a tumour suppressor in human gastric cancer. Cancer Lett, 2010, 298(1): 5063. ［8］ Kefas B, Godlewski J, Comeau L, et al. microRNA7 inhibits theepidermal growth factor receptor and the Akt pathway and is downregulated inglioblastoma. Cancer Res, 2008, 68(10): 35663572. ［9］ Jiang L, Liu X, Chen Z, et al. MicroRNA7 targets IGF1R (insulinlike growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J, 2010, 432(1): 199205. ［10］ Kong X, Li G, Yuan Y, et al. MicroRNA7 inhibits epithelialtomesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS One, 2012, 7(8): e41523. ［11］ Liu X, Yu J, Jiang L, et al. MicroRNA222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics Proteomics, 2009, 6(3): 131139. ［12］ Reddy SD, Ohshiro K, Rayala SK, et al. MicroRNA7, a homeobox D10 target, inhibits p21activated kinase 1 and regulates its functions. Cancer Res, 2008, 68(20): 81958200. ［13］ Wulfken LM, Moritz R, Ohlmann C, et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR1233 levels. PLoS One, 2011, 6(9): e25787.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[6]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[7]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[8]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[9]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[10]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[11]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[12]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[13]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[14]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[15]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.